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1148 Abstracts October 2013perhaps suggesting an incomplete SMC differentiation in some cell lines.
ASC-SMC demonstrated a 12% increase in contraction when plated onto
a collagen gel (P ¼ .04). Cells seeded onto the SIS scaffold and ﬂow condi-
tioned for 5 days exhibited extensive cellular retention and orientation in the
direction of ﬂow on both the abluminal and luminal surfaces (Fig).
Conclusions: These data demonstrate (1) the potential of autologous
ASC to acquire SMC characteristics (molecular markers, contraction) in
response to growth factor stimulation; and (2) the creation of a multilayered,
tissue-engineered vascular graft from a single, autologous adult stem cell
source. In vivo investigation of the graft within a canine model to evaluate
the addition of the medial layer is underway.
Fig.Efﬁcacy of Axillary to Femoral Vein Bypass in Relieving Venous
Hypertension in Dialysis Patients with Symptomatic Central Vein
Occlusion
Joshua C. Grimm, Robert J. Beaulieu, Ibrahim S. Sultan, Mahmoud B.
Malas, Thomas Reifsnyder. The Johns Hopkins Hospital, Baltimore, Md
Objectives: Central vein stenosis or occlusion remains an unfortunate
complication associated with the use of dialysis catheters. The risk is not trivial
as nearly 80% of patients commence therapy via a central venous catheter. In
patients with a functioning arteriovenous ﬁstula, central vein stenosis can lead
to debilitating arm, and breast and/or neck swelling. Treatment typically
involves central vein angioplasty and/or stenting, but restenosis and reocclu-
sion rates remain high. Presented here are the initial results of a unique series
of patients with a mature arteriovenous access and symptomatic upper
extremity venous hypertension who, after having failed endovascular therapy,
were treated with axillary vein to femoral vein bypass.
Methods: This is a retrospective analysis of seven hemodialysis patients
with functioning right upper extremity access who underwent axillary vein to
femoral vein bypass between December 2011 and January 2013. Indications
for venous bypass included upper extremity swelling in ﬁve of the patients and
a combination of breast and upper extremity swelling in two of the patients.
Results: The median age was 60 years (range, 42-82) and ﬁve of seven
patients were male. The etiology of end-stage renal disease (ESRD) included
hypertension (2), diabetes (2), lupus nephritis (2), and focal segmental glo-
merulosclerosis (1). At least ﬁve of the patients had documentation of prior
central venous catheter placement and all seven underwent a previous endo-
vascular procedure, which was either unsuccessful or technically unfeasible.
Ringed polytetraﬂuoroethylene was used in all seven cases and the average
hospital stay was 1.8 days (range, 1-3). All seven patients experienced resolu-
tion of their swelling, and there have been no major graft complications.
Conclusions: Axillofemoral venous bypass is a safe and effective treat-
ment option for the dialysis patient with symptomatic venous hypertension
due to central vein occlusion.
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Objectives: Hemodialysis vascular access (HVA) salvage after acute
thrombosis raises a debate between nephrologists and vascular surgeons
regarding the urgency of treatment. To assess the impact of early surgical
thrombectomy on the rate of HVA salvage, we offered an early surgical
protocol to eligible patients with acute HVA thrombosis.
Methods: Between January 2007 and October 2012, a total of 114
surgical thrombectomy attempts were performed on 82 patients to salvage
89 HVA. Time between the diagnosis of thrombosis and the admission inthe operation suite (T1), time between the diagnosis and the following dialysis
session (T2), and clinical and biological parameters were collected prospec-
tively for retrospective analysis. The main outcome measure was technical
success. Kaplan-Meier survival analysis estimated functional patency rates.
Results: Mean duration T1 was 5 hours 42 minutes (64 hours 24
minutes).Overall technical success ratewas 81% (92/114). A short-term cath-
eterwas placed following20 technical failures (18%).MeandurationT2was17
hours 18minutes (68 hours 48minutes). Early thrombectomywithin 6 hours
after diagnosis had a signiﬁcantly higher technical success rate (86%) compared
with thrombectomyperformed$6hours (69%;OR, 2.96; 95%CI, 1.10-7.97;
P¼ .03, logistic regression). Previous thrombosiswas also associatedwith tech-
nical failure (OR, 0.32; 95% CI, 0.12-0.86; P ¼ .02), whereas type of graft
(autologous/prosthetic) was not (P ¼ .89). The 30-day mortality rate was
2% (2/114). Mean patient follow-up was 22 6 18 months. Primary patency
rates were 56%6 7% and 41%6 7% at 1 and 2 years, respectively. Secondary
patency rates were 74% 6 7% and 56% 6 7% at 1 and 2 years, respectively.
Autologous ﬁstulae had higher secondary patency rates compared with pros-
thetic grafts (HR, 0.38; 95% CI, 0.18-0.82; P ¼ .01, Cox model).
Conclusions: With early surgical thrombectomy, there are increased
rates of HVA salvage that predict less reliance on catheter usage for
hemodialysis.
Fistula Maturation Algorithm Based upon Anatomic Fistula Location
Elizabeth Pensler, Yevgeniy Rits, Jeffrey Rubin. DMC/Wayne State
University School of Medicine, Detroit, Mich
Objectives: Initiation of dialysis therapy using autologous access is
crucial for establishing successful long-term dialysis therapy. The lead time
that is required for construction of the fully functional dialysis access prior
to dialysis is currently unknown. We have proposed to establish a lead
time algorithm for ﬁstula creation to be used based upon the anatomic loca-
tion of the ﬁstula as well as the type of conduit.
Methods: We reviewed the data for dialysis access creation over a 1-
year period in an inner city hospital. All patients prior to access placement
underwent arterial physiologic testing, arterial measurement, and venous
mapping. Criteria for use of venous conduits required vein diameters greater
than 2.5 mm. Arterial use was based upon a greater than 2-mm diameter as
well as appropriate physiologic parameters include extremity, hand, and
digital pressure measurements with and without radial and ulnar compres-
sion testing. A maturation algorithm was created, which was based upon
anatomic locations and essential preoperative factors.
Results: Over a 1-year period, 103 access procedures were performed.
There was a 60% rate for primary ﬁstula creation. Fifteen radiocephalic, 26
basilic vein transpositions, and 20 brachiocephalic primary access procedures
were performed, the rest were brachio-axillary grafts. Over this period, seven
accesses failed, three were lost to follow-up, and one patient died. The
average maturation time for all access procedures was 5.3 weeks. The
longest time to maturation involved the radiocephalic ﬁstula group, and
this required 10.3 weeks. Brachiocephalic ﬁstula maturation occurred an
8.6 weeks, and basilic vein transposition in 6.7 weeks. Prosthetic grafts
required 2.9 weeks until they were usable.
Conclusions: Based upon these results, we established the following
algorithm. All patients that reached chronic kidney disease stage IV that
were referred for access creation immediately underwent arterial and venous
ultrasound. Based upon vein suitability, patients were stratiﬁed into four
groups. Primary radiocephalic ﬁstula requires the longest time for full matu-
ration and suitability for use, followed by brachiocephalic and basilic vein
transposition. We, therefore, recommend patient referral to access centers
at least 6 months prior to anticipated dialysis requirement if we are to main-
tain the highest standards that have been established for the creation of
primary/autogenous arteriovenous ﬁstulas in this patient population.
Cost Discrepancies in the Creation and Maintenance of Functional
Arteriovenous Fistulas
Steven D. Abramowitz, Angela A. Kokkosis, Harry Schanzer, Peter L.
Faries, Michael M. Marin, Victoria J. Teodorescu. Mount Sinai Hospital,
New York, NY
Objectives: The National Kidney Foundation-Dialysis Outcomes
Quality Initiative recommends the preferential creation of arteriovenous
ﬁstulas (AVF) for hemodialysis access. Achieving and maintaining functional
patency of preferred hemodialysis access is a challenge for vascular surgeons
and a large healthcare expense. We sought to explore age-related and
gender-related differences in the costs of creating and of maintaining radio-
cephalic (RCF), brachiocephalic (BCF), and brachiobasilic (BBF) AVFs.
Methods: A prospectively maintained institutional database identiﬁed
348 patients undergoing access creation between 2004 and 2011 with 2
years of documented functional patency from the date of creation. Medical
records were analyzed for central venous catheter events, access-related
Fig 2.
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ing to access maturation. These events were designated as occurring within
either the ﬁrst or second year of functional access patency. Current proce-
dural terminology codes were used to calculate the unadjusted Medicare,
or “national average,” reimbursement in 2012 US dollars for these events
as outpatient hospital encounters. Bivariate analysis using linear modeling
and one-way analysis of variance was used to assess differences in mean
cost.
Results: RCFs and BCFs had higher 1-year functional patency costs
in females than in males ($19,257 vs $15,089 and $17,275 vs $13,819)
regardless of age. This remained statistically signiﬁcant with respect to 2-
year functional patency ($48,362 vs $42,372 and $43,361 vs $37,651).
RCF and BCF were costlier in patients over the age of 70 than BBF
($23,492 vs $22,984 vs $14,089) regardless of gender over the ﬁrst year
of access functional patency. This difference remained at 2 years as well
($53,251 vs $56,261 vs $39,372). Among females over age 70, the cost
of maintaining BBF was less expensive than in males or younger females
($13,247 vs $16,668 or $15,827) during the ﬁrst year as well as the second
year ($33,374 vs $44,726 or $44,324). All mentioned differences demon-
strated statistical signiﬁcance with a P value of <.05.
Conclusions: Sex, age, and anatomic location may correlate with cost
differences in maintaining 1- and 2-year functional patency of AVFs. These
ﬁnancial differences may further be stratiﬁed by patient demographics.
Nanolipoblockers: Ex Vivo Human Plaque Interaction for Therapeutic
Management for Atherosclerosis
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M. Grahama, Prabhas Moghec. aUNJ-RWJMS, New Brunswick, NJ;
bRutgers University, Piscataway, NJ; cRutgers University, Piscataway, NJ
Objectives: Atherosclerosis (AthSc) is escalated by the excessive accu-
mulation of oxidized low density lipoprotein (OxLDL). A new class of
nanopolymers, termed nanolipoblockers (NLB), has previously demon-
strated inhibition of OxLDL uptake by macrophages. Using an ex vivo
human carotid plaque model for targeted intervention with NLB offers
potential new mechanisms of AthSc treatment.
Methods: Carotid plaques were sectioned and incubated in culture
medium at 37C. Samples were treated with the NLBs of different polymer
chemistries and 5 mg/mL oxLDL to evaluate NLB binding to plaque and to
assess inhibition of plaque recruitment of OxLDL and effect on inﬂamma-
tion. Samples were digested, homogenized, ﬁltered, and ﬂuorescence quan-
tiﬁed by ﬂow cytometry and confocal microscopy to identify plaque
composition, NLB, and oxLDL uptake.
Results: Plaque cells were identiﬁed in the specimen showing high
levels of NLB binding, merely within 5 minutes, with an increase in uptake
in a chemistry-dependent manner after 24 hours (Fig 1). NLBs lowered
inﬂammatory markers in the presence of oxLDL. Furthermore, NLBs
caused a marked decrease in the uptake of OxLDL in plaque (Fig 2).
Conclusions: AthSc plaques could be targeted through NLB inter-
vention via a reduction in inﬂammatory substrates and multicellular OxLDLFig 1.uptake inhibition. This ex vivo model and the NLBs provide a promising
therapeutic strategy for the management of active AthSc.
Risk Score for Unplanned 30-Day Readmissions after Major Vascular
Surgery Procedures
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Objectives: Impending changes to hospital reimbursement has
focused attention on the signiﬁcant impact of unplanned hospital readmis-
sions on both patients and providers alike. Vascular surgery patients have
high readmission rates and identiﬁcation of high-risk groups that may be
amenable to targeted interventions is an important strategy for readmission
prevention. This study aimed to determine predictors of unplanned read-
mission and develop a risk score for predicting readmissions after vascular
surgery.
Methods: The National Surgical Quality Improvement Program
database for 2011 was queried for major vascular surgical procedures. The
primary end point was unplanned 30-day readmissions. The data was
randomly split into two-thirds for development and one-third for validation.
Multivariate logistic regression was used to create and validate a point score
system to predict unplanned readmissions.
Results: Overall 24,310 patients were included, with 2464 readmis-
sions (10.1%). A point based scoring system was developed based on
multivariate logistic regression for factors predictive for readmission
(Table). The scoring system developed included procedure type (open
abdominal aortic aneurysm ¼ 3 points, peripheral intervention 5 points,
amputation ¼ 1 point), graft failure prior to discharge (5 points), veno-
thromboembolism prior to discharge (4 points), discharge destination
(facility that was home ¼ 3-points, new facility or rehab ¼ 2 points), Black
race (1 point), nonelective presentation (1 point), pulmonary (2 points),
cardiac (2 points), renal (1 point) comorbidities, chronic steroid use (2
points), hypoalbuminemia (2 points), anemia (2 points), diabetes (1
point), bleeding disorder (1 point), operative time $150 minutes (1
point), and bleeding disorder (1 point). The point score was used to
stratify patients into three groups: low risk (0-3 points) with a readmission
rate of 5.4%, moderate risk (4-7 points) with a readmission rate of 8.6%,
and high risk ($8 points) with a readmission rate of 16.4%. The model had
good predictive ability (c-statistic ¼ 0.67).
Conclusions: Using patient, operative, and predischarge events, this
novel vascular surgery speciﬁc readmission score accurately identiﬁed
patients at high risk for 30-day unplanned readmission. This model could
help direct discharge and home health care resources to patients at high
risk, ultimately reducing readmissions and improving efﬁciency.
